title: Myelo-ablative therapy with peripheral blood progenitor cell (PBPC) support in patients with haematological malignancy.
abstract: BACKGROUND
  Myelo-ablative therapy with peripheral blood progenitor cell (PBPC) support is increasingly being used in patients with haematological malignancy considered to be at high risk for recurrence. The results of this approach, in comparison with the previous experience at St. Bartholomew's Hospital (SBH) using autologous bone marrow transplantation form the basis of this report.
  
  
  METHODS
  42 patients (age range 18-63 years, median 42 years), deemed to have a poor prognosis with conventional therapy received myelo-ablative therapy with PBPC support. Diagnoses comprised: non-Hodgkin's lymphoma (NHL): 16 patients, Hodgkin's disease (HD): 9, Multiple Myeloma (MM): 12, and solid tumours (ST): 5. PBPC were mobilised using adriamycin: 35 mg/m2 i.v. on day 1 and etoposide 100 mg/m2 orally, days 1-5, followed by G-CSF: 5 micrograms/kg, subcutaneously, for a median of 7 days (range 6-9 days).
  
  
  RESULTS
  A total of 67 PBPC collections were performed, 1 being 'sufficient' (i.e. mononuclear cells > or = 1.5 x 10(8)/kg and CD34+ cells > or = 1 x 10(6)/kg) in 21 of the 42 patients. The median time to haematological recovery following reinfusion of PBPC was 13 days for both neutrophils > 0.5 x 10(9)/l and platelets > 20 x 10(9)/l (ranges: 8-27, and 8-48 days, respectively) which is significantly shorter than for patients in the historical control group. Supportive care requirements were also significantly reduced, as was the duration of hospital stay i.e., median 19 days (range 12-73 days) compared with 29 days (range 9-180 days).
  
  
  CONCLUSIONS
  These results confirm rapid blood count recovery following myelo-ablative therapy with PBPC support and the feasibility of this approach.
authors.affiliation: ICRF Department of Medical Oncology, St. Bartholomew's Hospital, London, U.K.
authors.forename: A
authors.initials: A
authors.lastname: Pigaditou
authors.forename: G
authors.initials: G
authors.lastname: Marini
authors.forename: P W
authors.initials: PW
authors.lastname: Johnson
authors.forename: M
authors.initials: M
authors.lastname: Mahmoud
authors.forename: E
authors.initials: E
authors.lastname: Okukenu
authors.forename: K
authors.initials: K
authors.lastname: Adams
authors.forename: A
authors.initials: A
authors.lastname: Salam
authors.forename: J A
authors.initials: JA
authors.lastname: Amess
authors.forename: A J
authors.initials: AJ
authors.lastname: Norton
authors.forename: M F
authors.initials: MF
authors.lastname: Murphy
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D016022:Case-Control Studies; D003131:Combined Modality Therapy; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D016179:Granulocyte Colony-Stimulating Factor